N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 4 ClinicalTrials.gov

Intracervical Vasopressin

Sponsor: Prisma Health-Upstate • ClinicalTrials.gov ID: NCT07102615

Registry updated: 2026-10-02
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This randomized study looks at whether using a medicine injected into the cervix of the uterus (intracervical), called vasopressin, helps to achieve better removal of retained products of conception (RPOC). RPOC means that after a pregnancy has ended (through miscarriage, abortion, or delivery), some parts of the pregnancy tissue, usually from the placenta or fetus, have stayed in the uterus. A hysteroscopic removal of RPOC is one type of treatment. This is a surgical procedure where a doctor uses a small camera attached to a thin tube (called a hysteroscope) to look inside the uterus. The main goal of the study is : • To add to the existing research through this study to see if the injection of intracervical vasopressin leads to improved completion rates of hysteroscopic management of RPOC. Participants will: • would be randomized to receive either vasopressin intracervical injection or a placebo injection (non-active saline) during your procedure. Information from the procedure will be collected from the participant's medical record.

Interventions

  • Intracervical injection of Vasopressin (Drug)
    Intracervical injection of Vasopressin
  • Intracervical Injection of saline (Drug)
    Intracervical Injection of saline

Eligibility criteria

Inclusion Criteria: * Women * Aged 18-51 * Undergoing surgical management for retained products of conception, postpartum retained products of conception or 1st trimester missed or incomplete abortion Exclusion Criteria: * Hemodynamic instability * Active hemorrhage- soaking pad/hour * Allergy to vasopressin * Concern for intrauterine arteriovenous malformation * Inability to consent

Conditions

Retained Products of Conception

Locations

  • The OB/GYN Center — Greenville, South Carolina, United States
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record